Cargando…
Advancements in CRISPR-Based Biosensing for Next-Gen Point of Care Diagnostic Application
With the move of molecular tests from diagnostic labs to on-site testing becoming more common, there is a sudden rise in demand for nucleic acid-based diagnostic tools that are selective, sensitive, flexible to terrain changes, and cost-effective to assist in point-of-care systems for large-scale sc...
Autores principales: | , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953454/ https://www.ncbi.nlm.nih.gov/pubmed/36831968 http://dx.doi.org/10.3390/bios13020202 |
_version_ | 1784893881765068800 |
---|---|
author | Kumaran, Akash Jude Serpes, Nathan Gupta, Tisha James, Abija Sharma, Avinash Kumar, Deepak Nagraik, Rupak Kumar, Vaneet Pandey, Sadanand |
author_facet | Kumaran, Akash Jude Serpes, Nathan Gupta, Tisha James, Abija Sharma, Avinash Kumar, Deepak Nagraik, Rupak Kumar, Vaneet Pandey, Sadanand |
author_sort | Kumaran, Akash |
collection | PubMed |
description | With the move of molecular tests from diagnostic labs to on-site testing becoming more common, there is a sudden rise in demand for nucleic acid-based diagnostic tools that are selective, sensitive, flexible to terrain changes, and cost-effective to assist in point-of-care systems for large-scale screening and to be used in remote locations in cases of outbreaks and pandemics. CRISPR-based biosensors comprise a promising new approach to nucleic acid detection, which uses Cas effector proteins (Cas9, Cas12, and Cas13) as extremely specialized identification components that may be used in conjunction with a variety of readout approaches (such as fluorescence, colorimetry, potentiometry, lateral flow assay, etc.) for onsite analysis. In this review, we cover some technical aspects of integrating the CRISPR Cas system with traditional biosensing readout methods and amplification technologies such as polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), and recombinase polymerase amplification (RPA) and continue to elaborate on the prospects of the developed biosensor in the detection of some major viral and bacterial diseases. Within the scope of this article, we also discuss the recent COVID pandemic and the numerous CRISPR biosensors that have undergone development since its advent. Finally, we discuss some challenges and future prospects of CRISPR Cas systems in point-of-care testing. |
format | Online Article Text |
id | pubmed-9953454 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | MDPI |
record_format | MEDLINE/PubMed |
spelling | pubmed-99534542023-02-25 Advancements in CRISPR-Based Biosensing for Next-Gen Point of Care Diagnostic Application Kumaran, Akash Jude Serpes, Nathan Gupta, Tisha James, Abija Sharma, Avinash Kumar, Deepak Nagraik, Rupak Kumar, Vaneet Pandey, Sadanand Biosensors (Basel) Review With the move of molecular tests from diagnostic labs to on-site testing becoming more common, there is a sudden rise in demand for nucleic acid-based diagnostic tools that are selective, sensitive, flexible to terrain changes, and cost-effective to assist in point-of-care systems for large-scale screening and to be used in remote locations in cases of outbreaks and pandemics. CRISPR-based biosensors comprise a promising new approach to nucleic acid detection, which uses Cas effector proteins (Cas9, Cas12, and Cas13) as extremely specialized identification components that may be used in conjunction with a variety of readout approaches (such as fluorescence, colorimetry, potentiometry, lateral flow assay, etc.) for onsite analysis. In this review, we cover some technical aspects of integrating the CRISPR Cas system with traditional biosensing readout methods and amplification technologies such as polymerase chain reaction (PCR), loop-mediated isothermal amplification (LAMP), and recombinase polymerase amplification (RPA) and continue to elaborate on the prospects of the developed biosensor in the detection of some major viral and bacterial diseases. Within the scope of this article, we also discuss the recent COVID pandemic and the numerous CRISPR biosensors that have undergone development since its advent. Finally, we discuss some challenges and future prospects of CRISPR Cas systems in point-of-care testing. MDPI 2023-01-29 /pmc/articles/PMC9953454/ /pubmed/36831968 http://dx.doi.org/10.3390/bios13020202 Text en © 2023 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/). |
spellingShingle | Review Kumaran, Akash Jude Serpes, Nathan Gupta, Tisha James, Abija Sharma, Avinash Kumar, Deepak Nagraik, Rupak Kumar, Vaneet Pandey, Sadanand Advancements in CRISPR-Based Biosensing for Next-Gen Point of Care Diagnostic Application |
title | Advancements in CRISPR-Based Biosensing for Next-Gen Point of Care Diagnostic Application |
title_full | Advancements in CRISPR-Based Biosensing for Next-Gen Point of Care Diagnostic Application |
title_fullStr | Advancements in CRISPR-Based Biosensing for Next-Gen Point of Care Diagnostic Application |
title_full_unstemmed | Advancements in CRISPR-Based Biosensing for Next-Gen Point of Care Diagnostic Application |
title_short | Advancements in CRISPR-Based Biosensing for Next-Gen Point of Care Diagnostic Application |
title_sort | advancements in crispr-based biosensing for next-gen point of care diagnostic application |
topic | Review |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9953454/ https://www.ncbi.nlm.nih.gov/pubmed/36831968 http://dx.doi.org/10.3390/bios13020202 |
work_keys_str_mv | AT kumaranakash advancementsincrisprbasedbiosensingfornextgenpointofcarediagnosticapplication AT judeserpesnathan advancementsincrisprbasedbiosensingfornextgenpointofcarediagnosticapplication AT guptatisha advancementsincrisprbasedbiosensingfornextgenpointofcarediagnosticapplication AT jamesabija advancementsincrisprbasedbiosensingfornextgenpointofcarediagnosticapplication AT sharmaavinash advancementsincrisprbasedbiosensingfornextgenpointofcarediagnosticapplication AT kumardeepak advancementsincrisprbasedbiosensingfornextgenpointofcarediagnosticapplication AT nagraikrupak advancementsincrisprbasedbiosensingfornextgenpointofcarediagnosticapplication AT kumarvaneet advancementsincrisprbasedbiosensingfornextgenpointofcarediagnosticapplication AT pandeysadanand advancementsincrisprbasedbiosensingfornextgenpointofcarediagnosticapplication |